Histopathologic characteristics of choroidal melanoma in eyes enucleated after iodine 125 brachytherapy in the collaborative ocular melanoma study

Archives of Ophthalmology

Volumn 126, Issue 2, 2008, Pages 207-212

  Avery, Robert B ^a   Diener West, Marie ^b   Reynolds, Sandra M ^b   Grossniklaus, Hans E ^c   Green, W Richard ^b   Albert, Daniel M ^d,e  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125;

ARTICLE; BLOOD VESSEL INJURY; BRACHYTHERAPY; CANCER INVASION; CHOROID MELANOMA; CONTROLLED STUDY; ENUCLEATION; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRIS DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETINOPATHY; TUMOR GROWTH; UVEA MELANOMA; VITREOUS HEMORRHAGE;

BRACHYTHERAPY; CHOROID NEOPLASMS; EYE ENUCLEATION; HUMANS; IODINE RADIOISOTOPES; IRIS; MELANOMA; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION INJURIES; RETINA; TREATMENT FAILURE; VITREOUS HEMORRHAGE;

EID: 39049107047     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archophthalmol.2007.50     Document Type: Article

References (16)

1. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine125 brachytherapy for choroidal melanoma, III: initial mortality findings. Arch Ophthalmol. 2001;119(7):969-982.
2. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine125 brachytherapy for choroidal melanoma, IV: twelve-year mortality rates and prognostic factors. Arch Ophthalmol. 2006;124(12):1684-1693.
3. Collaborative Ocular Melanoma Study Group. The COMS trial of iodine 125 brachytherapy for choroidal melanoma, IV: local treatment failure and enucleation in the first 5 years after brachytherapy. Ophthalmology. 2002;109(12):2197-2206.
4. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition. Control Clin Trials. 1993;14(5):362-391.
5. Collaborative Ocular Melanoma Study Group. COMS Manual of Procedures, PB95-179693. Springfield, VA: National Technical Information Service; 1995.
6. Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. Am J Ophthalmol. 1998;125(6):745-766.
7. Collaborative Ocular Melanoma Study Group. COMS Study Forms Book, PB91-217315. Springfield, VA: National Technical Information Service; 1991.
8. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96(4):502-509.
9. Crawford JB, Char DH. Histopathology of uveal melanomas treated with charged particle radiation. Ophthalmology. 1987;94(6):639-643.
10. Shields CL, Shields JA, Karlsson U, Menduke H, Brady LW. Enucleation after plaque radiotherapy for posterior uveal melanoma. Ophthalmology. 1990;97(12):1665-1670.
11. Stallard HB. Radiant energy as (a) a pathogenic and (b) a therapeutic agent in ophthalmic disorders. Br J Ophthalmol. 1933;6(suppl):1-26.
12. Saornil MA, Egan KM, Gragoudas ES, et al. Histopathology of proton beam-irradiated vs enucleated uveal melanomas. Arch Ophthalmol. 1992;110(8):1112-1118.
13. Gündüz K, Shields CL, Shields JA, et al. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol. 1999;117(5):609-614.
14. Schachat AP. Radiation retinopathy. In: Ryan SJ, ed. Retina. St Louis, MO: Mosby-Year Book; 1989:541-546.
15. Puusaari I, Heikkonen J, Kivela T. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma. Invest Ophthalmol Vis Sci. 2004;45(10):3425-3434.
16. Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histopathologic measurements from eyes with medium-sized choroidal melanoma in the Collaborative Ocular Melanoma Study: COMS Report No. 21. Arch Ophthalmol. 2003;121(8):1163-1171.